NCT00632749 - BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG

BI 811283 (d 1 and 15)

BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle

DRUG

Cytarabine

Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle

DRUG

BI 811283 (d1)

BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle

DRUG

Cytarabine

Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle

Trial Locations (7)

1247.3.49007 Boehringer Ingelheim Investigational Site, Berlin

1247.3.49005 Boehringer Ingelheim Investigational Site, Frankfurt am Main

1247.3.49004 Boehringer Ingelheim Investigational Site, Freiburg im Breisgau

1247.3.49006 Boehringer Ingelheim Investigational Site, Hamburg

1247.3.49003 Boehringer Ingelheim Investigational Site, Heidelberg

1247.3.49002 Boehringer Ingelheim Investigational Site, Münster

1247.3.49001 Boehringer Ingelheim Investigational Site, Ulm